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HEALING CHRONIC WOUNDS: 
THE POTENTIAL USE OF HYPOTHERMIC PROCESSING 
OF AMNIOTIC TISSUE TO TREAT CHRONIC WOUNDS 
AMY KASPARIAN 
 
ABSTRACT 
 
Chronic diabetic foot ulcers, venous leg ulcers and pressure ulcers affect a large 
subset of the United State population yet they remain a challenge for physicians to treat. 
There are many different types of products on the market for the treatment of chronic 
wounds.  Some use living cells but only two are FDA approved to heal chronic wounds.  
A new type of product recently garnered attention in the wound care market because it 
also contains living cells: hypothermically stored amniotic tissue products. 
Hypothermically stored amniotic tissue is unique because it maintains living cells and 
offers the benefits of containing signaling molecules and maintaining an intact extra 
cellular matrix.  While there are other types of amniotic or placental tissue products in the 
wound care market, they are processed by dehydration or cryopreservation which limits 
their capacities for maintaining living cells.  This thesis will explore the potential for 
hypothermically processed amniotic tissue products to treat chronic wounds. 
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AIMS AND OBJECTIVES 
 
 
 
• To describe differences in the body’s response to healing acute and chronic 
wounds 
 
• To review the major types of products on the market for treating chronic wounds 
 
• To describe the structure and properties of placental and amniotic tissue products 
relevant to healing chronic wounds 
 
• To analyze the potential benefits of using hypothermically processed human 
placental tissue to treat chronic wounds 
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I. INTRODUCTION  
 
A. Importance of Wound Healing 
According to the Centers for Disease Control and Prevention, approximately 30.3 
million people, or 9.4% of the United States population, had diabetes in 2015.1  Diabetes 
was the cause of 14.2 million emergency department visits and 108,000 lower-extremity 
amputations, or 5.0 per 1,000 persons with diabetes, in 2014.1 Moreover, in 2012, the 
United States spent $245 billion on direct and indirect expenditures for treating diabetes 
and the average annual cost to treat an individual diagnosed with diabetes was about 
$13,700.1 Similarly, 1% to 2% of the adult population suffers from venous leg ulcers 
(VLUs).2  The average time it takes to heal a VLU is 190 days and the annual cost of 
treating VLUs is over $2 billion, with actual, direct treatment costs of approximately 
$10,000 per person per ulcer.3  Thus, there is clearly an economical and clinical need to 
improve the way we treat chronic wounds.  This thesis will analyze the potential of using 
hypothermically processed human placental tissue for the treatment of chronic wounds. 
 
B. Wound Healing in the Human Body 
i. Acute Wounds  
An acute wound is a wound that heals within a predictable amount of time, which, 
in a healthy adult, typically takes about two (2) weeks.4  Without intervention, acute 
wound healing in the human body occurs in four phases: hemostasis, inflammation, 
proliferation and remodeling, as shown in Figures 1 and 2.  The process involves 
	2 
complex interactions between cells and chemical signals.3,5   
 
Figure 1. Phase of wound healing in days.  Reproduced from AmnioBand Membrane – MTF 
Wound Care. http://mtfwoundcare.org/www/tissue-forms/amnioband-2/. Accessed February 22, 
2018. 
The first phase, hemostasis, begins immediately after injury and helps to 
minimize blood loss by creating a physiological barrier against bacterial infection.5,6 
Platelets bind to the exposed collagen and, with the help of chemokines and growth 
factors, form a clot.6,7  The next phase, inflammation, is characterized by an initial influx 
of neutrophils which help to cleanse the site of debris and bacteria followed by a later 
accumulation of macrophages and mast cells which continue to phagocytose the bacteria 
and help cleanse the site by removing damaged tissue.5  Neutrophils release enzymes 
such as elastase and collagenase which help them move through the extracellular matrix 
(ECM).8  Proteases, particularly the matrix metalloproteinases (MMPs), degrade and 
	3 
remodel the extracellular matrix and play a key role in tissue repair and wound healing.9  
MMPs also assist in wound healing by eliminating damaged protein, remodeling 
granulation tissue, regulating some growth factors and potentially controlling 
angiogenesis.5,6  Later, macrophages assist in the wound’s transition into the proliferative 
phase by secreting growth factors and cytokines, some of the major ones include platelet-
derived growth factor (PDGF), transforming growth factors (TGF)-β and (TGF)-α, 
fibroblast growth factor (FGF), and insulin like growth factor (IGF)-1, which attract 
fibroblasts and endothelial cells.6  During the proliferative phase, angiogenesis, 
epithelialization and synthesis of the extracellular matrix occur.  The original clot is 
replaced with granulation tissue which develops from components of the extracellular 
matrix such as proteoglycans, hyaluronic acid, collagen and elastin.5,10,11  Fibroblasts, 
endothelial cells and keratinocytes also play a key role in reepithelization.5  Finally, 
during the remodeling phase, the granulation tissue matures into a scar as components of 
the extracellular matrix continue to be deposited and type III collagen is gradually 
replaced with type I collagen, a stronger alternative.8  The formation of a scar depends on 
a careful balance between pro-inflammatory cytokines, growth factors, proteases and 
their inhibitors.3,12 
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Figure 2. Phases of acute wound healing.  Adapted from Goldberg SR, Diegelmann RF. Wound 
Healing Primer. Surg Clin North Am. 2010;90(6):1133-1146. doi:10.1016/J.SUC.2010.08.003. 
Joshua Loveall, graphic artist. 
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ii. Chronic Wounds 
If a wound does not show signs of healing within a normal amount of time, it is 
classified as a “chronic wound” or a “chronic cutaneous ulcer.”3,12  There is no clear 
definition of what physicians consider a “normal amount of time” for a wound to heal, 
however, most physicians would agree that a wound that fails to heal within 3 weeks to 4 
months should be considered a chronic wound.13,14   A common algorithm for 
determining if a wound is chronic is to look at the wound 4 weeks after standard 
treatment.  If there has not been at least a 40% reduction in the wound area after 4 weeks 
of standard care, then clinicians should commence advanced treatment.15  There are three 
major categories of chronic wounds: venous leg ulcers (VLUs), diabetic foot ulcers 
(DFUs) and pressure ulcers.  VLUs typically occur in elderly patients and are caused by 
valve dysfunction in the leg. They account for 70-90% of chronic wounds.3,15  Diabetic 
foot ulcers occur in about 15-20% of diabetic patients and are difficult to treat because 
each DFU patient shows unique characteristics.  Diabetic patients suffer from neuropathy 
which inhibits their ability to perceive pain.  Therefore, they are unlikely to notice a 
developing wound or infection on their feet.  One of the main reasons understanding and 
treating DFUs is important is because they are known to account for 50% of total cases of 
non-traumatic lower limb amputation.3  Pressure ulcers occur in patients subject to 
excessive bedrest, which include coma patients and patients who are paralyzed.  If a body 
part is subjected to high pressure for a long period of time, it will develop a pressure ulcer 
because the restriction of blood flow to the tissue causes ischemia and tissue 
breakdown.5,8 
	6 
Chronic wounds are often stalled in the inflammatory phase of healing which is 
characterized by an increase in neutrophils, macrophages and lymphocytes.5  Typically, 
these leukocytes help fight infection at the wound site by removing bacteria, foreign 
materials and components of the extracellular matrix. However, if these leukocytes build 
up in excess, they can cause extensive loss of tissue and prevent the wound from entering 
the remodeling phase because the massive amounts of inflammatory cells cause 
degradation of the extracellular matrix and destruction of growth factors essential to 
healing.8  Particularly, the overabundance of macrophages triggers an increased secretion 
of inflammatory cytokines which leads to an increase in the secretion of proteases such as 
MMPs which continue to degrade the extracellular matrix beyond what is typical in acute 
wounds.  Likewise, an excess of neutrophils leads to a buildup of reactive oxygen species 
and proteases such as elastase.16  Figure 3 shows the interaction of MMPs, neutrophils, 
macrophages and proteases during the development of a chronic wound. 
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Figure 3. Stalled inflammation in chronic wound healing.  Reproduced from McCarty SM, 
Percival SL. Proteases and Delayed Wound Healing. Adv Wound Care. 2013;2(8):438-447. 
doi:10.1089/wound.2012.0370. 	
Management of infection and biofilm is an essential part of treating chronic 
wounds.  Biofilm is a thin layer of microorganisms, and the polymers they secrete 
(polymeric substance), which adhere to the surface of a wound.3  It is thought to be 
composed of approximately 5–25% bacterial cells and 75–95% extracellular polymeric 
substance.  If an infection is not treated, the developing high concentrations of microbes 
will compete with host cells for oxygen and activate the inflammatory process which can 
lead to host cell degradation and death.3,17  Biofilm is dangerous because it can be a 
breeding ground for bacteria by protecting it from antimicrobial agents and supporting 
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bacterial growth and communication.16  Therefore, it is necessary to remove necrotic, 
infected tissue and biofilm from a wound.  To do so, clinicians use a process called 
debridement, or  “the removal of foreign material and devitalized or contaminated tissue 
from or adjacent to a traumatic or infected lesion until surrounding healthy tissue is 
exposed.”5  Debridement is often done surgically, but can also be completed 
enzymatically, autolytically, biologically and mechanically.18 
 
II. ADVANCED THERAPY OPTIONS 
 
There are many types of dressings on the market to treat acute and chronic 
wounds.  Historically, commercial wound care products started off as cotton gauze 
soaked in saline or sodium hypochlorite.  Over the years, dressings evolved and started 
including treatments that would help keep the wound moist, like hydrogels and alginates, 
and antimicrobial compounds like silver.  There are close to 1,500 different types of 
dressing on the market today which likely makes choosing a product difficult for 
clinicians.  If dressings fail to heal an acute wound within a few weeks, clinicians move 
on to advanced wound treatments to care for the now chronic wound.3  
Some of the leading advanced wound care products on the market include: 
negative pressure wound therapies (NPWT), exogenous growth factors, acellular matrix 
products, bioengineered skin substitutes and amniotic tissue products.  These products 
vary in their abilities to treat difficult-to-heal chronic wounds depending on their 
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composition and ability to maintain or provide a sustainable environment for 
regeneration. 
 
A. Negative Pressure Wound Therapy 
Negative Pressure Wound Therapy (NPWT), sometimes referred to as vacuum-
assisted closure (VAC) or microdeformational wound therapy (MDWT), refers to a 
relatively new treatment for chronic, acute and burn wounds that uses a vacuum dressing 
to promote wound healing.  The process has become popular in the past 15 years.  A 
NPWT device is made up of a foam dressing, a sealing film, a drainage tube and a 
suction.  NPWT works by creating a negative pressure environment around the wound, 
removing exudate/fluid from the area and improving angiogenesis and neurogenesis.18–20  
There are four primary mechanisms of action in NPWT treatment, including: (1) 
shrinking the wound, or macrodeformation; (2) microdeformation at the foam-wound 
interface; (3) exudate/fluid removal; and (4) stabilization of the wound environment.  
Moreover, scientists speculate NPWT has secondary effects as well including the 
stimulation of angiogenesis, the promotion of neural growth and favorable alterations in 
bioburden.19,20  
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Figure 4. Negative Pressure Wound Therapy. This figure shows how NPWT is set up, 
including (A) the application of the oxygen pressure sensor, (B-C) a cut out in the foam dressing 
to fit the sensor, and (D) the application of a drainage tube and a film to seal the area.  
Reproduced from Han S-K. Innovations and Advances in Wound Healing. Berlin, Heidelberg: 
Springer Berlin Heidelberg; 2016. doi:10.1007/978-3-662-46587-5. 	
NPWT has been shown to improve healing in diabetic foot ulcer patients by 
improving the rate of wound healing, measured as the time it took for a wound to 
complete closure and the time it took to form granulation tissue as reflected in the time it 
took to form such tissue on the wound bed.  Clinical studies have also shown that NPWT 
limits the severity of adverse event occurrences, like the development of infections, in 
wound patients.3  NPWT is also beneficial because it reduces cell death by preventing 
tissue dehydration and it is relatively low maintenance because it only needs to be 
changed every few days.18  It is important to note that the first NPWT devices introduced 
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in the United States were vacuum-assisted closure devices, V.A.C.® Therapy (Acelity, 
TX, USA) which were all produced by the same company in San Antonio, Texas.  Many 
of the clinical studies available to physicians are specific to V.A.C.® devices, may be 
biased and may not be applicable to all NPWT devices in general.21,3,18  Although the 
efficacy of NPWT has been largely accepted in the medical community, more studies and 
data are needed to understand the mechanisms of action and explore different 
preparations of the therapy.3,16  Moreover, NPWT does not provide the wound bed with 
cells, signaling molecules or a matrix to facilitate regeneration like other products on the 
market. 
 
B. Exogenous Growth Factor Therapy 
Growth factors and cytokines are molecules that stimulate cells in many ways, 
including, cellular proliferation, angiogenesis and extracellular matrix synthesis.3,5  
Recently, the medical community has become highly interested in researching the use of 
exogenous growth factors to assist in treating chronic wounds.  Growth factors show 
promising potential for patients with non-healing wounds because of their potential to 
signal cells to stimulate proliferation and ultimately induce wound healing by signaling 
extracellular matrix synthesis and attracting macrophages, fibroblasts, vascular 
endothelial cells and other important processes in wound healing.22,23  There are several 
products on the market today being used on and off label to treat wounds, including, 
topical treatments containing platelet-derived growth factor (PDGF), basic fibroblast 
growth factor (bFGF) and epidermal growth factor (EGF), to name a few.22,24  
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One example of an exogenous growth therapy product on the market today is 
becaplermin, or Regranex® Gel (Smith & Nephew, London, UK), which was approved 
by the Food and Drug Administration (FDA) in 1997 for the treatment of DFUs.24  
Regranex® is a gel that contains a recombinant human platelet-derived growth factor 
(rhPDGF-BB) for treatment of lower extremity diabetic neuropathic ulcers that extend 
into the subcutaneous tissue or beyond.  The efficacy of Regranex® has not yet been 
established for use in VLUs, pressure ulcers or DFUs that do not extend through the 
dermis.23  However, studies on becaplermin gel, in conjunction with good wound care, 
have shown that its use can significantly increase the number of complete wound closures 
in DFU patients and reduce the time to complete such wound closure.22,25  Nevertheless, 
there are not enough current studies to date on the use of becaplermin, or other growth 
factors for that matter, in treating chronic wounds.  The studies that do exist have 
different end points and use varying modes of growth factor administration.  Larger, 
randomized controlled studies are needed to investigate the efficacy and safety of growth 
factor therapy and propose ideal delivery methods.12  
 
C. Bioengineered Skin Substitutes 
Bioengineered skin substitutes, also commonly referred to as biological dressings, 
are substitutes derived from living tissue.  As further explained below, they can be 
described as “living” or “non-living” depending on whether they contain living cells 
when applied to the surface of a wound. 
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i. Acellular  
Non-living bioengineered skin substitutes, or acellular matrix products, are 
dressings that originated from living tissue but do not contain living cells when used 
clinically.  They are often used to treat surgical and burn wounds and are beneficial to 
patients because they protect against infection and trauma, provide a moist environment 
and scaffold for healing, and prevent water loss.26  Acellular skin substitutes are more 
readily available the cellular skin substitutes.  They typically are made up of collagen 
scaffolds, fibroblasts and keratinocytes.15   
Acellular matrix products have shown efficacy in healing chronic wounds.  They 
are thought to be effective because they provide a preformed extracellular matrix to the 
wound that provides a structural scaffold supporting growth and regeneration.  Since they 
are acellular, the matrices have a long shelf life and their use and application is relatively 
easy.27,15,27  Not all acellular matrix products are the same: they can be made from various 
components of the extracellular matrix, they can be dermal or non-dermal, they can be 
manufactured using human or animal sources, and they may be coated with different 
types of antimicrobials.28  One example of an acellular matrix product is Integra™ 
Meshed Bilayer Wound Matrix (Integra LifeSciences Corporation, NJ, USA) which is 
composed of bovine derived collagen, glycosaminoglyacans and a silicone layer.  It may 
be used with NPWT therapy and is indicated for use in the management of chronic 
wounds, including pressure ulcers, VLUs, DFUs burns, surgical wounds, trauma wounds, 
and more.29 Another example of an acellular matrix product is PuraPly AMTM Wound 
Matrix (Organogenesis Inc., MA, USA), a single-layer sheet of porcine collagen coated 
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with an antimicrobial, polyhexamethlyenebiguanide hydrochloride (PHMB), which helps 
manage biofilm.  PuraPly AMTM is indicated for the management of diabetic ulcers, 
venous ulcers, pressure ulcers and other types of wounds.30   
Although many innovative developments have been made to acellular matrix 
products over the years, there still are limitations in their ability to heal wounds.  For 
example, acellular matrix products often result in wound contraction, scar formation, and 
poor integration with host tissue.27  Moreover, it is unclear whether the efficacy of tissue 
scaffolds is any better than other types of products on the market.  Of note, a study was 
done testing a biological dressing product, in this case, Oasis Wound Matrix®, against a 
growth factor therapy, Regranex® Gel, discussed above.  For the 73 patients in the trial, 
no difference was found in ulcer healing or time to healing.12 
ii. Cellular 
Cellular, or living, skin substitutes were made in an effort to emulate the 
physiological environment needed to heal a wound.  Cellular skin substitutes can be 
classified as epidermal, dermal or composite grafts which contain both dermal and 
epidermal components.31  Figure 5 shows a schematic representation of a few types of 
skin substitutes and lists some of their key components. 
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Figure 5. Skin substitute structural variation diagram. Adapted from Jones I, Currie L, Martin 
R. A guide to biological skin substitutes. Br J Plast Surg. 2002;55(3):185-193. 
doi:10.1054/bjps.2002.3800.  
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1. Epidermal Grafts 
The concept of epidermal grafts first came about when James Rheinwatd and 
Howard Green published a study about successfully culturing colonies of human 
keratinocytes at the Massachusetts Institute of Technology in 1975.32  Epicel® (Vericel 
Corporation, MA, USA) is an example of an epidermal autograft indicted for use in deep 
dermal or full thickness burns that comprise 30% or more of the body’s total surface area.  
As an autograft, it is composed of grafts of the patient’s own skin cells combined with 
irradiated murine, or mouse, cells which help promote skin growth.33  Over time, the 
technology was developed for use in wound care.  Modern products now use allogenic 
cultured keratinocyte grafts from newborn foreskin.  Studies using epidermal grafts on 
diabetic ulcers on the lower extremities have suggested that cultured allogeneic skin cells 
are an effective treatement.12  It is thought that they promote healing because the neonatal 
keratinocytes secrete more growth factors than adult keratinocytes which helps to 
increase proliferation of granulation tissue.12,34  
2. Dermal Grafts 
Dermal tissues grafts contain dermal tissue components.  Dermagraft® 
(Organogenesis Inc., MA, USA) is an example of a dermal skin substitute.  Dermagraft® 
is a cryopreserved human fibroblast-derived dermal substitute composed of fibroblasts, 
ECM and a bio-absorbable scaffold.  It is manufactured from fibroblast cells derived 
from newborn human foreskin tissue and is indicated for use in diabetic foot ulcers.  
Mesh in the product provides a scaffold on which the fibroblasts can grow and secrete 
growth factors and dermal proteins like collagen and glycosaminoglycans.  In this way, 
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the dermal skin substitute stimulates vascular tissue and epithelial tissue growth at the 
wound bed.  Ultimately the mesh, which is composed of biodegradable material, 
dissolves a few weeks after treatment.35–37  Studies have shown that Dermagraft®, a 
human fibroblast-derived dermis, is a safe and effective treatment for diabetic foot 
ulcers.12  
 
 
Figure 6. HSE (Apligraf®) product storage and placement demonstration.  Adapted from 
Shai A, Maibach H. Wound Healing and Ulcers of the Skin: Diagnosis and Therapy - The 
Practical Approach. Berlin/Heidelberg: Springer-Verlag; 2005. doi:10.1007/b138035. 	
3. Composite Grafts 
Composite grafts are composed of a combination of dermal and epidermal tissue.  
Apligraf® (Organogenesis Inc., MA, USA) is an example of a composite graft for which 
a wealth of clinical studies has been completed over the years.  Figure 6 above shows a 
demonstration of Apligraf® being applied to a wound.  Apligraf® can also be classified 
as a human skin equivalent (HSE), which is a living skin-equivalent composite graft that 
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contains a dermal component with living fibroblasts and a epidermal component with 
living keratinocytes.38  The concept of using HSEs for wound care was first published by 
Bell in 1981 when scientists were able to successfully graft living skin-equivalents, 
containing fibroblasts cast in collagen lattices and seeded with epidermal cells, onto the 
cell donors.39  Apligraf® is an allogenic human bi-layer containing dermal and epidermal 
components.  It contains human keratinocytes and fibroblasts derived from newborn 
foreskin and bovine type I collagen.  Apligraf® does not contain professional antigen-
presenting cells, such as Langerhans cells, passenger leukocytes, dermal dendritic cells 
and endothelial cells, which are necessary for activation of allogeneic T-cells and tissue 
rejection.39–41  Apligraf® was the first bi-layered bioengineered skin substitute approved 
by the FDA as a Class III medical device via premarket approval to promote healing of 
chronic ulcers.12,39,40  It is highly regarded in the field because multiple studies have 
shown that Apligraf® heals DFU and VLU wounds more rapidly and in more patients 
than compression therapy alone, some of which are illustrated in Table 1 below.42  
OrcelTM (Ortec International, Inc., New York, NY) is an example of another major bi-
layered cellular matrix on the market which received premarket approval a few years 
after Apligraf®, in 2001.  It is composed of a bilayered matrix in which human 
keratinocytes and dermal fibroblasts are cultured into two layers of a bovine collagen 
sponge.  OrcelTM, however, is different from Apligraf® because it is indicated for split 
thickness donor site wounds in burn patients, rather than chronic ulcers which are the 
focus of this thesis.12,43 
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Table 1. Efficacy of Apligraf®, a Human Skin Equivalent.  Reproduced from Shai A, Maibach 
H. Wound Healing and Ulcers of the Skin: Diagnosis and Therapy - The Practical Approach. 
Berlin/Heidelberg: Springer-Verlag; 2005. doi:10.1007/b138035. 
 
D. Amniotic Tissue 
Another option for treating chronic wounds is amniotic tissue derived products 
which are classified as human cells, tissues, and cellular and tissue-based products 
(HCT/P's) by the FDA because they are minimally derived human based tissue 
products.44,45  Various types of processing human amniotic tissue for use in wound 
healing have been used, as discussed below.  A novel, new method of processing 
amniotic tissue, hypothermic processing, shows promising potential for use in wound 
care and is the focus of this thesis. 
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III. AMNIOTIC TREATMENT 
 
A. Amniotic Tissue Background  
The use of human amniotic membranes in wound care treatment dates back to the 
early 1900s when Davis used them for reconstructive surgery.45  Over the years, the 
popularity of amniotic tissue in a clinical setting increased rapidly as it was developed for 
use in ulcers, corneal burns and cutaneous burns.46  However, the risk of disease and 
infection, especially in light of  the AIDs crisis of the 1980s, coupled with problems in 
preparing and storing the tissue, prevented human amniotic tissue from becoming 
mainstream for many years.  Nevertheless, recent developments in clinical practice have 
brought placental-derived grafts back into the wound care market in recent years. 
The amniotic layer begins to develop about 5-8 days after fertilization in a 
developing fetus.  When the blastocyst, a hollow ball of embryonic stem cells, implants 
on the uterus, the inner layer of cells develop into the embryo and the outer layer of cells 
develop into what soon will be the placenta.  The placenta later develops into two layers 
of membranes: the outer layer is called the chorion and the inner layer is called the 
amnion.  These membranes create the amniotic sac, sometimes referred to as the 
placental sac.  The amniotic sac fills with amniotic fluid in which the embryo floats.46  
On a macro level, the amniotic, or placental, sac contains the fetus and the amniotic fluid 
as shown in Figure 7.47   
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Figure 7. Amniotic sac, macro level.  Reproduced from Stages of Development of the Fetus - 
Women’s Health Issues - Merck Manuals Consumer Version. 
http://www.merckmanuals.com/home/women-s-health-issues/normal-pregnancy/stages-of-
development-of-the-fetus. Accessed February 22, 2018. 	
The amniotic membrane consists of five layers: epithelium, basement membrane, 
compact layer, fibroblast layer and intermediate (spongy) layer.48,49  The epithelium is a 
thin, single layer of epithelial cells.  The basement membrane is composed of collagen 
types III, IV and V, laminin, fibronectin and nidogen.  It is one of the thickest basement 
membranes found in human tissue – strong enough to support the developing fetus 
throughout gestation.  The compact layer is composed of collagen types I, III, V, and VI 
and fibronectin.  It forms the main fibrous structure of the amnion and has minimal cell 
content.  The fibroblast layer consists of fibroblasts, collagens types I, II and V, and 
glycoproteins.  Mesenchymal cells in the fibroblasts layer secrete the collagens that make 
up the compact layer.  Finally, the spongy, or intermediate layer, divides the amniotic 
layer and the chorionic layer.  It consists of proteoglycans, glycoproteins and mostly type 
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III collagen.48,50   
The chorion is in contact with the amnion on its innermost layer and the maternal 
decidua on its outermost layer.  It consists of a reticular layer, a basement membrane, and 
a trophoblast layer.  The reticular layer is the thickest layer of the chorion and is 
composed of collagens I, II, IV, V and VI.  The basement membrane is a thick layer of 
connective tissue that is bound to the reticular layer and anchors the trophoblast using 
collagen IV, fibronectin and laminin.  Finally, the trophoblast layer consists of 2 to 10 
layers of trophoblast cells that are in contact with the maternal decidua.51  Figure 8 below 
presents the layers of the amniotic and chorionic membrane and their ECM compositions.  
Interestingly, the amniotic and chorionic layers of the placental sac can be easily 
separated as shown below in Figure 9.48,52 
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Figure 8. Layers of the amniotic and chorionic membrane and their ECM components.  
Reproduced from Niknejad H, Peirovi H, Jorjani M, Ahmadiani A, Ghanavi J, Seifalian A. 
Properties of the amniotic membrane for potential use in tissue engineering. Eur Cells Mater. 
2008;7:88-99. doi:10.22203/eCM.v015a07. 
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Figure 9. Separation of the amniotic layer of the placental sac.  In B, the amniotic 
membrane is being mechanically peeled from the chorion.  Reproduced from Tabatabaei M, 
Mosaffa N, Nikoo S, et al. Isolation and partial characterization of human amniotic epithelial 
cells: the effect of trypsin. Avicenna J Med Biotechnol. 		
B. Benefits of Using Amniotic Tissue in Wound Care 
The use of amniotic tissue in wound care has been shown to be beneficial because 
it offers some of the major necessities for a regenerative environment: living cells, 
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signaling molecules and an extracellular matrix.  It is also an ideal choice clinically 
because it acts as a barrier against bacterial contamination, has low immunogenicity, 
reduces pain and has anti-inflammatory properties.53,54   
 
 
Figure 10. Amniotic tissue histology.  Reproduced from Riau AK, Beuerman RW, Lim LS, 
Mehta JS. Preservation, sterilization and de-epithelialization of human amniotic membrane for 
use in ocular surface reconstruction. Biomaterials. 2010;31(2):216-225. 	
i. Cells 
One of the major reasons human amniotic tissue is useful in a wound care setting 
is that it is a source of stem cells for regenerative medicine.  Amniotic mesenchymal stem 
cells are advantageous because they are anti-inflammatory, trophic, multi-potent, anti-
fibrotic and pose minimal ethical concerns.55  These cells are fresh, young, not affected 
by donor age and responsive to the environment.  It has been shown that amniotic 
epithelial cells from human placental tissue express the same surface markers found on 
embryonic stem cells and germ cells.48,53  Figure 10 above presents a histological 
visualization of amniotic tissue with fibroblast and epithelial cells dispersed.  Epithelial 
amniotic cells are an ideal choice for regenerative medicine because, in addition to 
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having all the advantages of stem cells, they also have native properties ideal for 
integration with the host tissue including, for example, an extracellular matrix with an 
almost native scoffold.55  Studies have also shown that amniotic epithelial cells are 
multipotent and have the potential to differentiate into all three germ layers, the 
endoderm, mesoderm and ectoderm, which further supports the notion that amniotic 
tissue has the potential to enhance wound healing.53,55  Moreover, as shown in Figure 11 
below, the mesenchymal stem cells secrete molecules that affect immune cells, like T-
cells, B-cells and dendritic cells, and increase anti-inflammatory activity.  They also 
secrete molecules that assist in creating a regenerative environment by supporting 
angiogenesis and mitosis.9  
 
 
Figure 11. Mesenchymal stem cells have trophic and immuno-modulary effects.  Adapted 
from Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell. 2011;9(1):11-15. 
doi:10.1016/j.stem.2011.06.008. 
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ii. Signaling molecules 
Another benefit of using human amniotic tissue for wound healing is its ability to 
provide growth factors and cytokines to the wound bed.  In a study of diabetic foot ulcers 
and matrix metalloproteinases (MMPs) by Muller et al.,9,56,57 it was found that the level 
of MMP-8 and MMP-9 secretion by inflammatory cells in an acute wound decreases 
early in good healers but remains present for an extended period in chronic wounds.  It 
has been found that chronic wounds contain higher levels of proteases and pro-
inflammatory cytokines and lower levels of growth factors and that MMPs regulate the 
activity of growth factors.58  Thus, it can be inferred that chronic wounds likely need 
more cytokines and growth factors to assist with healing.  In a study comparing growth 
factor mRNA and protein content in preserved human amniotic membranes with 
epithelial cells and without epithelial cells, it was found that the human amniotic 
membrane with the epithelial cells expresses mRNAs for growth factors and additional 
growth factor proteins, such as EGF, Keratinocyte Growth Factor (KGF), Hepatocyte 
Growth Factor (HGF) and bFGF, compared to the amniotic membrane without 
epithelium.  These growth factors and growth factor proteins are thought to benefit 
healing and epithelization.59  Growth factors play a significant role in controlling 
inflammation, stimulating cell proliferation, promoting angiogenesis, increasing cell 
migration and improving the depositing and remodeling of the extracellular matrix.  A 
few of the growth factors and cytokines found in amniotic tissue that play an important 
role in wound healing are listed and organized according to their benefit to healing in 
Table 2.48 
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Table 2. Growth factors and cytokines important in wound healing.  Reproduced from 
McQuilling JP, Vines JB, Mowry KC. In vitro assessment of a novel, hypothermically stored 
amniotic membrane for use in a chronic wound environment. Int Wound J. 2017;14(6):993-1005. 
doi:10.1111/iwj.12748. 
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iii. Extracellular Matrix 
The extracellular matrix (ECM) has an open structure which influences the 
adhesion, migration and growth of stem cells, the content of growth factors and the 
content of genetic materials.  The use of ECM from human tissue, instead of tissue from 
another species or an artificially produced scaffold, increases the likelihood of 
biocompatibility.  Biocompatibility is the property of being biologically compatible with 
living tissue.  Human tissue is less likely to be destroyed by inflammation, injure the host 
or be carcinogenic.  Instead, it is more likely to influence the appropriate host response 
by increasing stability, elasticity and improving the adhesion of cellular growth 
factors.14,48  Certain molecules and structures found in the human ECM, like collagen, 
laminin, proteoglycans, glycosaminoglycans and fibronectin, support its use in wound 
management and may affect the attachment of cells and growth factors.48  Therefore, the 
preservation of an open and intact matrix is most beneficial to wound healing.  
Furthermore, the ECM of human amniotic tissue contains integrins which are 
transmembrane receptors that have an extracellular and intracellular domain to link the 
ECM and cytoskeleton respectively.  Integrins serve an important role in wound care 
products because they have both mechanical and signaling functions.60 
 
C. Types of Processing Amniotic Tissue for Use in Wound Care 
There are three major ways to process and manufacture human placental tissue for 
use in wound care: dehydration, cryopreservation and hypothermic preservation.  These 
processes differ in the level of living or non-living cells present after processing, the 
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number of layers maintained in the product and the integrity of the ECM.  Most types of 
placental tissue processing maintain the amniotic layer, but not all of them maintain the 
chorion, epithelial or spongy layers which can significantly impact the level and types of 
growth factors present in the final product.  Moreover, the structure and spacing of the 
ECM vary dramatically amongst products and the type of processing can affect the 
content of living and non-living cells in the product.   
The American Association of Tissue Banks (AATB) regulates the acquisition and 
preparation of amniotic tissue products.  Amniotic tissue must be acquired from an 
AATB accredited facility that adheres to the FDA’s rigorous quality standards.  Tissues 
can only be acquired from consenting, healthy donors who have been pre-screened and 
tested for infectious diseases including, but not limited to, human immunodeficiency 
virus, hepatitis C, and syphilis.60,61  Tissue is typically donated from full-term human 
placentas with the umbilical cord after delivery, ideally via caesarean section, of a 
healthy baby.14,49  Processing of the tissue post acquisition must be in compliance with 
the FDA’s current Good Manufacturing Practice (GMP).  A more in-depth analysis of the 
different types of processing is provided below.   
i. Dehydration: maintains growth factors 
The PURION® Process, developed in 2006, is an example of a proprietary 
method for dehydrating amniotic tissue for use in treating wounds.  The PURION® 
Process produces a commercially available dehydrated human amnion/chorion membrane 
(dHACM) allograft called EpiFix® (MiMedx Group Inc., Marietta, GA) by separating 
the placental tissues obtained from a screened and tested donor under sterile conditions, 
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cleaning it, reassembling the layers, and then dehydrating the tissue.  The process leaves 
behind an ECM with key proteins in quantities equivalent to the unprocessed 
amnion/chorion membrane and removes blood components.49  An array of 36 cytokines 
known to regulate inflammation and wound healing were found in the dHACM 
allograft.62  dHACM  application can be very effective in healing chronic wounds.  See 
Figure 12 below which demonstrates complete healing of a planter ulcer with 48 weeks 
duration after three dHACM applications.63  The major drawback of dHACM is that 
dehydration alters the structural integrity of the tissue resulting in a thin, compact layer of 
amniotic tissue, as demonstrated in Figure 13 below.63  The process involves terminal 
sterilization and results in  protein denaturation,  damage to the structure and a product 
that has no living cells.64  Since the dehydration process collapses the ECM, a dHACM 
allograft loses its ability to function as an innate scaffold and is not able to maintain 
living cells.65  Thus, the main benefit of dHACM allograft products is their ability to 
deliver amniotic growth factors and cytokines. 
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Figure 12. Complete healing of a chronic wound after three applications of a dHACM 
product.  Adapted from Zelen CM, Serena TE, Snyder RJ.  A prospective, randomised 
comparative study of weekly versus biweekly application of dehydrated human amnion/chorion 
membrane allograft in the management of diabetic foot ulcers. Int Wound J. 2014;11(2):122-128. 
doi:10.1111/iwj.12242. 		
ii. Cryopreservation: maintains growth factors and matrix 
integrity  
Cryopreservation, or the use of low temperatures to structurally preserve living 
cells or tissues, is another method for processing amniotic tissue.63  This method was 
developed to maintain the structural integrity of the ECM.63  Cryopreserved human 
amniotic tissue (cHAM) may be processed with dimethylsulphoxide (DMSO) at -80°C.  
Cryopreservation of amniotic tissue has been reported to retain the structural integrity of 
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the ECM, thus showing functional superiority to dHACM.  This is important in wound 
healing because the ECM is a reservoir for growth factors and proteins that regulate the 
regenerative process.  Figure 13 below, which compares histological stainings of 
dHACM, cryopreserved amniotic membrane and cryopreserved umbilical cord, 
demonstrates the notion that cryopreservation does not cause notable changes in the 
structural integrity of the ECM when compared to dHACM.63  Moreover, 
cryopreservation retains the distribution of hyaluronic acid which has been shown to 
contribute to the anti-inflammatory and anti-scarring properties of the amniotic 
membrane.63,66  It should be noted, however, that protocols for cryopreservation vary 
dramatically with different types of cryopreservation methods impacting the ability for 
cHAM allografts to retain viable cells and growth factors.66,67  In one study in 2001 it was 
found that approximately 50% of the epithelial cells of cryopreserved amniotic 
membrane remained viable several months after processing.66,68  Alternatively, a separate 
study in 2000 showed that no viable cells were detected following cryopreservation and 
no epithelial or fibroblastic cells grew after cryopreservation.59  Thus, while 
cryopreservation of human amniotic tissue is effective because it maintains the structural 
integrity of the ECM, which is a reservoir for growth factors, it is still limited in its 
ability to preserve and maintain living cells. 
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Figure 13. Comparison of cryopreserved amniotic membrane CT-AM, cryopreserved 
umbilical cord CT-UM, and dehydrated human amnion chorion membrane dHACM.  
Reproduced from Cooke M, Tan EK, Mandrycky C, He H, O’Connell J, Tseng SCG. Comparison 
of cryopreserved amniotic membrane and umbilical cord tissue with dehydrated amniotic 
membrane/chorion tissue. J Wound Care. 2014;23(10):465-476. 
doi:10.12968/jowc.2014.23.10.465. 		
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iii. Hypothermic processing: maintains growth factors, matrix 
integrity and viable cells 
Hypothermically stored amniotic membranes (HSAMs) were developed to 
preserve native growth factors, ECM integrity and viable native cells.  They are a novel, 
new treatment for chronic wounds because, in addition to maintaining signaling 
molecules and matrix structure, they also maintain living cell content.48,59,69  Affinity® 
(Organogenesis Inc. Canton, MA) is an example of a fresh, hypothermically stored 
allograft developed from the amniotic membrane derived from the human placenta.  It is 
unique because it is the only fresh amniotic membrane that contains: (1) growth factors 
and cytokines that stimulate angiogenesis, promote regeneration and manage 
inflammation; (2) the amnion’s native ECM with its native proteins; and (3) viable living 
cells.48  The cells in the epithelial layer of the amniotic membrane have similar 
characteristics to stem cells that can be differentiated into all three germ layers.59,70  To 
develop Affinity®, placentas are acquired from consenting donors after planned 
caesarean sections in accordance with the AATB standards and the FDA’s Good Tissue 
Practices.  Donors are tested for infectious diseases, including human immunodeficiency 
virus, human T-lymphotropic virus I/II, hepatitis B and C, and syphilis, prior to 
acquisition of the tissue.  Affinity® products are then hypothermically processed and 
stored in a propriety AlloFreshTM process.  Of note, the HSAM is aseptically processed, 
rather than sterilized as is the case in dHACM and cHAM, which is likely done to 
preserve the viability of the native living cells.  The AlloFreshTM process also does not 
subject the fresh tissue to harsh freezing and thawing processes likely to denature cells, 
proteins and the native ECM.  Thus, the amnion’s open ECM is left unaltered 59   
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IV. HYPOTHERMICALLY PROCESSED AMNIOTIC TISSUE COMPARED 
 
A. Benefits of Hypothermic Processing of Amniotic Tissue in Wound Care 
An in vitro study of HSAM has demonstrated that it is effective in addressing key 
issues affecting chronic wounds.59  In a study done by McQuilling et al., HSAM was 
found not only to contain angiogenetic, regenerative and anti-inflammatory growth 
factors and cytokines essential to wound healing, but also to release them over an 
extended period of time resulting in increased migration and proliferation.  It was found 
that the cytokines released from HSAM increase human fibroblast migration and 
proliferation, as shown in Figure 14 below.5,11,59  This is significant because fibroblasts 
play a significant role in the wound healing process by initiating the proliferative phase 
after inflammation and depositing new ECM.59  Moreover, HSAM showed a significant 
increase in human epidermal keratinocyte proliferation and migration compared to assay 
media alone.10,59  This is significant because keratinocytes are thought to become an 
active part of the wound healing cycle by secreting ECM components, depositing a 
preliminary basement membrane, and producing growth factors.59  Finally, the study also 
showed that higher concentrations of media conditioned from HSAM correlates to an 
increased average blood vessel tubule length suggesting that HSAM may have a 
significant impact on angiogenesis in the woundbed.59,71  This is important because 
chronic wounds commonly show impaired angiogenesis which leads to a drastic shortage 
in nutrient supply at the wound bed and increased cell death.  The ability of HSAM to 
facilitate angiogenesis could have a crucial impact on wound healing.48 
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Figure 14. The effect of HSAM on fibroblast migration and proliferation.  (A) Graph of 
fibroblast proliferation in various concentrations of HSAM conditioned media; (B) images of 
fibroblast proliferation in such various HSAM medias using CFDA(green) and Dapi (blue) stains; 
(C) chart of fibroblast migration over 24 hours for such various HSAM medias; and (D) images 
of cell migration using crystal violet staining to show cells. Significance compared to assay media 
is denoted by *P <0.05, **P <0.01, ***P <0.001 and ****P <0.0001. Reproduced from 
McQuilling JP, Vines JB, Mowry KC. In vitro assessment of a novel, hypothermically stored 
amniotic membrane for use in a chronic wound environment. Int Wound J. 2017;14(6):993-1005. 
doi:10.1111/iwj.12748. 
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B. Comparison of Amniotic Tissue Processing  
Amniotic tissue products vary based on the method used to preserve and process 
the tissue.  The most common methods for processing amniotic products are dehydration, 
cryopreservation and hypothermic processing.  The differences in the preservation 
methods affect the integrity of the ECM, the viability of cells preserved and the growth 
factors maintained.72  In a study comparing a dehydrated amnion/chorion membrane to a 
hypothermically stored amniotic membrane on rat models, HSAM grafts were shown to 
promote greater tissue regeneration than the dHACM grafts.63  This is likely because the 
dehydration process used to make dHACM alters the structural integrity of the tissue 
resulting in a thin, compact layer of amniotic tissue.  Sterilization during the dehydration 
process destroys living cells, causes protein denaturation and damages the ECM 
structural integrity.64  During processing, the ECM collapses and is no longer able to 
maintain living cells.63,66 
Compared to cryopreserved human amniotic tissue, HSAM provides the 
additional benefit of preserving viable, living cells.  The process of cryopreservation 
involves freezing and thawing the human tissue which destroys native cells.  The ability 
of cHAM to maintain living cells after processing is controversial.  In fact, protocols for 
cryopreservation vary so much that different studies have reported different results in the 
ability for cHAM allografts to retain viable cells and growth factors.66–68  As described 
above, one study found that approximately 50% of the epithelial cells of cryopreserved 
amniotic membrane remained viable after processing, while a separate study showed that 
no viable cells survived or grew following cryopreservation.63 
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The differences between cryopreserved and dehydrated fetal tissue are both 
structural and biochemical.  Histological analysis of the two processes revealed that 
dehydration results in a compacted, thin ECM while cryopreservation maintains the open, 
natural structure of the extracellular matrix.  Moreover, dHACM does not maintain as 
many growth factors and cytokines as cHAM which negatively impacts the tissue’s 
ability to improve wound healing by limiting angiogenic, regenerative and anti-
inflammatory activities.48,73 
Moreover, although many of the same growth factors have been found in dHAM, 
cHAM and HSAM, the processing methods for different products differ based on which 
placental layers companies choose to include in their products.   Some companies keep 
both the amnion and chorion membranes, like NuShield® (Organogenesis Inc., Canton, 
MA), others exclude the amnion layer, like Grafix® Core (Osiris Corporation, WI, USA), 
some exclude the chorion layer, like Grafix® Prime (Osiris Corporation, WI, USA), and 
still others, like EpiFix®, exclude the spongy layer which is known for its abundance of 
proteoglycans, glycoproteins and collagen.35,41,74  These variations in the types of layers 
maintained in placental products drastically affect the growth factor content available to 
stimulate growth, regeneration and angiogenesis.  
 
C. HSAM in the Wound Care Market in General 
  The ideal amniotic product would emulate fresh amnion and chorion membrane 
by maintaining all the layers with minimal processing to maintain living cells, an intact 
matrix and the highest concentration of growth factors and cytokines. As discussed 
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herein, Affinity®, a hypothermically stored amniotic membrane process, seems to be 
closest amniotic product to realizing this ideal.   
Of all the products on the market developed for treatment and/or healing of 
chronic wounds, Apligraf® and Dermagraft® are the only two living cell products with 
FDA approval to heal chronic wounds.64 Moreover, Apligraf® is the only product that 
contains dermal (fibroblasts) and epidermal (keratinocytes) living cells which is why this 
thesis will focus on Apligraf® going forward. 
Hypothermically stored amniotic tissue products are similar to human skin 
equivalents because they contain living cells.  One of the major difference is, however, 
that Apligraf® is composed of a dermal and epidermal layer which is made up of human 
skin components while Affinity® is composed of fresh amnion and chorion membranes.  
Figure 15 below shows a comparison of the structural layers of Apligraf® and Affinity®.  
Both products contain growth factors but no studies have been done comparing the 
quantity or types of growth factors present in the two products.  Nevertheless, it could be 
reasonably hypothesized that Apligraf® has more of the types of signaling molecules 
necessary to heal a wound because it is derived from actual skin tissue whereas Affinity® 
is two membranes of placental tissue.  Alternatively, Affinity® shows promising 
potential because it is derived from living, unaltered, amniotic tissue and has had less 
alterations during the manufacturing process that Apligraf®.  Moreover, although they 
are not skin cells, the epithelial cells of the amniotic membrane in Affinity® have similar 
characteristics to stem cells which can be differentiated into all three germ layers and 
may be beneficial to wound healing.   
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Figure 15. Composition comparison of Apligraf® and Affinity®.  Amy Kasparian, graphic 
artist. 	
While no studies have been published on the comparative effectiveness of a 
bioengineered living cell substitute like Apligraf® and a hypothermically stored amniotic 
product like Affinity®, there has been a publication on the comparative effectiveness of 
Apligraf® and a dehydrated human amniotic membrane allograft, EpiFix®. In this study 
by Kirsner et al., it was found that DFUs treated with a bioengineered living cellular 
construct had higher healing rates in less time compared to those treated with dHACM.1  
A possible explanation for this difference is the lack of viable cells and compressed ECM 
structure found in dHACM.  Therefore, one might reasonably conclude that a 
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comparative effectiveness study of bioengineered living cell substitutes and HSAM might 
level the playing field because HSAM offers what dHACM does not: living cells.  Thus, 
there is reason to believe that, if the right studies are done, HSAM products might be 
proven to be very effective at treating chronic wounds. 
 
V. CONCLUSION  
 
More studies are needed to better understand how the various processing 
techniques, particularly hypothermically processed amniotic tissue, affect a product’s 
ability to deliver signaling molecules, a native ECM structure and viable cell 
components.  Ideally, large volume, prospective, comparative analysis studies that level 
the playing field in terms of type of wound, patient demographics (such as medical 
history, prior treatment, concurrent treatment, and prior surgeries) would be run on 
HSAM products to determine their effectiveness in healing chronic wounds.  Moreover, 
such studies would report specific information regarding the extent of biofilm 
debridement and adverse events.  Nevertheless, HSAM’s ability to maintain signaling 
molecules, viable native cells, and an intact extracellular matrix suggests that it may be 
an excellent new treatment option for treating chronic wounds. 
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